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Background: Punctual delivery of dopaminergic medication to Parkinson's disease (PD) patients may be
important in optimizing disease control. We tested the hypothesis that prompt delivery of L-dopa
medications to emergency hospital inpatients was associated with a decreased length of stay in hospital.
Methods: The study population consisted of all urgent hospitalizations for patients with a diagnosis of PD
to the Royal Derby Hospital over a two-year period. Data were extracted on timing of delivery of drugs,
number of co-morbidities and length of stay. Statistical analysis used linear regression adjusting for
within admission clustering.
Results: 431 individuals provided data from a total of 737 admissions. 39% of scheduled L-dopa doses
were either not given or administered over 30 min later than the scheduled time. There was no asso-
ciation between the omission or timing of a dose of PD medication and length of stay in hospital. The
number of coded diagnoses was strongly associated with length of stay with a dose-response association
(pTREND<0.001). Those with 10 concurrent diagnoses had a 11 day longer stay (95% conﬁdence
intervals: þ2 to þ21) than those with no comorbidities.
Conclusions: Delayed administration of dopaminergic drugs is not associated with prolonged length of
stay of in patients with PD who were admitted to hospital as an emergency. However, the number of co-
existing medical diagnoses was associated with length of stay, and early attention to these has the po-
tential to improve patient care and decrease length of stay in hospital.
© 2016 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
People with Parkinson's Disease (PD) are one and half times
more likely than others to be admitted to hospital, they stay longer
and have more complications [1e3]. The cost of PD admissions in
England is estimated to be more than £200 m per year and the
number of hospitalizations is increasing [4,5]. Omission of dopa-
minergic medication, delays in administration of dopaminergic
medication and inappropriate use of anti-dopaminergicmedication
commonly occur when Parkinson's disease patients are hospital-
ized [1,6e13]. Omission of dopaminergic medication is associated
with worse motor performance both in hospital and in theLtd. This is an open access article ucommunity [14,15]. PD patients commonly report delays in getting
their medication and one in four believe such delays lead to longer
hospital stays [16,17].
A recent US study reported increased length of hospital stay in
PD patients with at least one dose of PD medication that was
omitted or delayedmore than an hour. Administration of dopamine
antagonists was also associated with increased length of stay [18].
We have recently completed a study into the impact of a specialist
unit for the care of Parkinson's disease patients on a number of
quality indicators [19]. A post hoc analysis of these data demon-
strate that patients who received their Parkinson's medication late
had a longer length of stay than those who received it promptly,
and that 12% of the variation in length of stay was explained by
timing of medication delivery.
We used data from the introduction of an electronic prescribing
and administration system in a busy District General Hospital tonder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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istration of medications to in-patients with Parkinson's disease and
their length of stay. We focused on L-dopa medications because of
its short half life and repeated the analysis with dopamine agonists
(ropinirole, rotigotine, pramipexole, apomorphine).
2. Methods
2.1. Study population
The study population consisted of all patients with a diagnosis
of PD that were admitted to the Royal Derby Hospital from the
period of 25th March 2012 to 31st March 2014 for at least one day
and were subsequently discharged. The hospital patient adminis-
tration system was used to identify cases with a primary or sec-
ondary diagnosis of PD. For these admissions, prescription datawas
extracted using an electronic prescription system (iCM, Isoft) and
only those on dopaminergic or anti-dopaminergic medicationwere
included in the study. Dopaminergic medications included in the
study were: Levodopa (co-beneldopa, co-careldopa, Stalevo),
dopamine agonists (ropinirole, rotigotine, pramipexole, apomor-
phine). Drugs that were regarded as contraindicated in the context
of PD were: amisulpiride, chlorpromazine, haloperidol, levome-
promazine, metoclopramide, olanzapine, prochlorperazine, pro-
mazine, risperidone and sulpiride. We used the hospital electronic
prescribing system to extract the following data: age, sex, number
of associated diagnoses at discharge, medications, scheduled
medication administration time, actual medication administration
time, omitted doses, reason for omission of medication, and length
of stay. Self-medicating patients were excluded from the analysis.
Ethical approval was not required as only routinely collected ano-
nymised data was used.
2.2. Statistical analysis
Linear regression was used to explore the association of time-
liness of delivery of L-dopa medication with length of stay. We
deﬁned late medication delivery as 30 min or more after scheduledFig. 1. Age of studdelivery time or documented omission of the drug dose. Each drug
administrationwas considered as one event and data frommultiple
time points for each individual's hospital admission were adjusted
for using robust standard errors. This generated a measure of the
association between an additional missed or omitted dose of
medication and length of stay for each hospital admission period.
Secondary analyses looked at: the association between timing of
dopamine agonists and length of stay; the association between
prescription of contraindicated dopamine antagonists with length
of stay; the effect of weekends v weekdays on prompt delivery of
PD medications. All analyses were adjusted for gender, age as a
categorical variable and the number of recordedmedical diagnoses.
Sensitivity analyses were performed using a broader deﬁnition of
late medication administration with a 60-min delay from sched-
uled time. We were unable to complete a stratiﬁed analysis by L-
dopa dose frequency as 47% of the population has a personally
designed drug regimen. All statistical analysis used Stata statistical
software (v13, Texas).
3. Results
For the main analysis, data were available on a total of 737
admission episodes from a population of 431 individuals. Of these,
the median age was 82 years (interquartile range 77e87, Fig. 1) and
236 (55%) were male. The median number of coded co-morbidities
was 7 (interquartile range 5e10). The median length of stay for all
admissions was 8 days (interquartile range 4e17, Fig. 2).
29587 doses of L-dopawere prescribed over the study period. Of
these doses, 11382 (38.75%) were delayed (omitted or administered
more than 30 min later than the scheduled time). For those who
received their L-dopa, the median difference for administering any
of this medication was þ9 min (interquartile range IQR: 16
to þ41) after the scheduled time. 2848 (9.7%) doses had docu-
mented omission codes. Main reasons for omission of medication
were as follows: medicine not available, 554 doses (19%); medicine
refused by patient 322 doses (11%); patient nil by mouth 309 (11%);
route not available 238 doses (8%). Also see supplementary table
online.y population.
Fig. 2. Length of stay in hospital for study population.
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sociation between the number of late or omitted L-dopa drug ad-
ministrations and length of stay in hospital after adjusting for
confounding factors. Sensitivity analyses redeﬁning latemedication
as omitted or delayed more than 60 min (N ¼ 7060 doses, 24%)
similarly demonstrated no association with length of stay. The
presence of a weekend made no difference to the lateness of de-
livery of L-dopa compared to weekdays (data not presented).Table 1
Multivariate model of association of delay in administration timing of L-dopaa with
length of stay in hospital adjusting for sex, age and number of co-morbidities.
No. of dose (%) Length of stay, days
(95% CI)
Drug given late (>30 min or omitted)
Yes 11382 (39) 0.88 (2.51 to þ0.75)
No 18005 (61) 0
No. of individuals (%)
Age
<69 41 (10) 0
70e79 108 (25) 10.29 (26.56 to þ5.98)
80e89 225 (52) 10.92 (26.20 to þ4.37)
90þ 57 (13) 13.16 (28.55 to þ2.24)
Sex
Female 195 (45) 0
Male 236 (55) 0.18 (5.36 to þ5.00)
Number of co-morbidities
1 3 (1) 0
2 11 (3) 12.87 (24.93 to 0.82)
3 29 (7) 5.31 (14.57 to þ3.96)
4 45 (10) þ4.91 (7.87 to þ17.69)
5 45 (10) þ7.64 (3.34 to þ18.62)
6 58 (13) þ8.48 (2.15 to þ19.12)
7 57 (13) þ7.02 (4.06 to þ18.11)
8 39 (9) þ10.90 (þ1.57 to þ20.23)
9 36 (8) þ17.83 (þ3.88 to 31.77)
10 33 (8) þ10.56 (þ1.44 to 19.67)
11 75 (17) þ22.47 (þ12.29 to þ32.65)
pTREND<0.001
CI ¼ conﬁdence intervals.
Analysis used linear regression adjusted clustering by each patient's hospital visit.
a Co-beneldopa/co-careldopa/Stalevo.Similarly, delayed administration (deﬁned as >30 min) or
omission of dopamine agonists (apomorphine, premipexole, ropi-
nirole, rototigine) was not associated with length of stay in hospital
after adjusting for confounding factors.
40 (9%) patients out of a total population of 431 patients with a
diagnosis of PD received contraindicated drugs. Administration of
contraindicated dopamine antagonists was not associated with
increased length of stay after adjustment for sex, age and number of
other diagnoses (Table 2). Similarly, those who received allowed
antipsychotic drugs or anti-dementia medication did not have a
longer length of stay.
The number of coded diagnoses was strongly associated with
length of stay (pTREND <0.001). There was a dose-response associ-
ation and those with 10 concurrent diagnoses had a 11 day longer
stay (95% conﬁdence intervals: þ2 to 21) than those with no
comorbidities.
4. Discussion
The study is the ﬁrst to use an electronic prescribing system toTable 2
Association of other prescribed drugs with length of stay in a population of patients
admitted with Parkinson's Disease.
No. of medication episodes (%) Length of stay (95% CI)
Contra-indicated drugsa
Yes 1167 (4) 2.58 (11.11 to þ5.95)
No 29387 (96) e
Allowed antipsychotic medicationb
Yes 1302 (4) þ2.51 (2.11 to þ7.13)
No 30657 (96) e
Anti-dementia medicationc
Yes 2879 (9) 1.23 (5.43 to þ2.97)
No 30657 (91) e
Linear regression model adjusted for sex, age and number of concurrent co-
morbidities.
a Amisulpiride, chlorpromazine, haloperidol, metaclopramide, olazanepine, pro-
chlorperazine, promazine, risperidone.
b Clozapine, Quetiapine.
c Donepazil, Galantamine, Memantine, Rivastigmine.
R. Skelly et al. / Parkinsonism and Related Disorders 35 (2017) 25e2928explore the association between timing of dopaminergic medica-
tionwith length of stay in a population of patients with Parkinson's
disease. The results demonstrate 39% of L-dopa medication is given
late or not at all. However, after adjustment is made for age, sex and
the number of co-morbidities, the timing of L-dopa administration
is not associated with the length of stay in hospital. The number of
co-morbidities is however strongly associated with length of stay
even after adjusting for age, and this has important implications for
providing appropriate medical care for these patients.
The strengths of these data include the fact that it is the largest
study to date looking at the impact of timing of delivery of Par-
kinson's medication in this patient group. The data were collected
using the electronic prescribing system that permits accurate
measurement of the timing of the delivery of medication, and
comparison with the prescribed time. We were also able to explore
the impact of the prescription of medications that are generally
contraindicated in patients with PD. The electronic data collection
system allowed adjustment for the number of discharge diagnoses
for each patient, as well as age and sex, and the association of these
covariates with length of hospital stay as well.
These analyses do have a number of limitations. Firstly, the
pragmatic use of coding diagnoses of PD rather than application of
strict diagnostic criteria such as the UK Brain Bank Criteria was
necessary to identify all eligible patients. However, in the primary
analysis all patients in our study were on dopaminergic medication
so we are conﬁdent that it is very likely that these patients had a
diagnosis of PD. Secondly, these data are from a single centre and
may not be representative of standard practice elsewhere. Thirdly,
we have used a number of statistical analyses on these data, so are
unable to exclude the possibility of a false positive test as a
consequence of multiple hypothesis testing. Unfortunately, we did
not have an accessible measure of disease severity. Clearly if most
individuals had early stage Parkinson's without wearing off
symptoms, then missed or delayed doses might be well tolerated.
Similarly, the use of electronic diagnostic coding data limits our
ability to distinguish between admissions that are directly a
consequence of PD, and those due to an unrelated diagnosis. Also
the coding data did not allow consideration of other potentially
important confounding factors such as place of residence and
cognitive function. Finally, the choice of length of stay was an
opportunistic outcome measure, and the use of a quality of life
measure or evaluation of control of Parkinson's symptoms while in
hospital would better reﬂect patients' priorities.
Our use of linear regression for the statistical analysis was
selected to allow us to test if the hypothesis that delayed PD drug
administration resulted in increased length of stay. The 95% conﬁ-
dence intervals will necessarily span zero if the exposure of interest
was not signiﬁcantly associated with the outcome, creating a
negative length of stay which represents a p value greater than
0.05. We initially aimed to stratify the analysis by drug frequency,
but were unable to do so as 47% of the population has a medication
regimen tailored to their clinical needs. As a consequence, we were
unable to explore the associations of frequency of PD medications
with length of stay any further. In the context of a clear rejection of
the hypothesis being tested, we did not proceed to any further
analysis looking at L-dopa equivalent doses [7].
It is important to consider why the timing of delivery of Par-
kinson's medications is not associated with length of stay, as this is
clearly important to patients and their families [7,16], recognized by
clinicians as an important factor in improving control of PD [14] and
others have reported that it is associated with decreased length of
stay [18]. Firstly, we studied a population of patients with a diag-
nosis of PD who were admitted as emergency admissions to hos-
pital. Clearly, this is a very heterogeneous group with a range of
medical and surgical reasons for admission, and, Parkinson'sDisease was often a documented co-morbidity rather than the
primary diagnosis. This is opposed to a population of patients who
are admitted with a primary problem associated with Parkinson's
disease where choice and timing of medication, as well as other
interventions such as physiotherapy are clearly essential. The
absence of any association between timing of Parkinson's medica-
tions and length of stay certainly does not make this issue any less
of a priority in the care of this patient group. Secondly, prompt
administration of medication may only be important for those with
wearing off symptoms and/or motor ﬂuctuations. Thirdly, some
patients, for example thosewith delirium, may have beneﬁted from
the reduced dopaminergic stimulation associated with missed
medication [20].
While it is well recognized by physicians that clinical deterio-
ration can be associated with delayed delivery of medications and
initiation of anti-psychotic drugs, we are unable to demonstrate
this in our dataset. Only 9% of the patients had contraindicated anti-
psychotic medication and we were unable to distinguish between
established antipsychotic medication and new prescriptions.
In a study of hospitalizations of people with Parkinson's,
Ramirez-Martinez et al. report that participants who had delayed
or missed at least one dose stayed in the hospital for longer (me-
dian 5 days) compared to those who did not (median 2 days) [18].
That study differed from our study: most prescriptions speciﬁed a
frequency rather than a precise time. Also it is not clear to us if there
was any statistical adjustment for the number of scheduled doses,
as clearly with longer periods of time spent in hospital the proba-
bility of missed medication increases as a consequence of increased
exposure.
The most striking observation in these analyses is the very
strong dose-response association between the number of coded
diagnoses on discharge from hospital with length of stay even after
adjustment for age. Although we are unable to distinguish between
new diagnoses acquired during the hospital admission in question
and pre-existing diagnoses, this has large implications for the care
of people with Parkinson's admitted to hospital as geriatricians and
general internists used to managing multiple conditions may be at
least as important in caring for such people as movement disorder
experts. Geriatric liaison services in orthopaedics and in perioper-
ative care appear to improve care and may do so for the hospital-
ized Parkinson's patient [21].
In summary we found no association between omitted and
delayed dopaminergic medication with length of hospital stay.
Many of those with Parkinson's admitted to hospital were elderly
and the number of coded diagnoses was strongly associated with
length of stay. This is an obvious but important area where better
geriatric liaison services might have the potential to improve care
for the hospitalized Parkinson's patient.
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